Larimar Therapeutics

Contributing Author

Recent Articles by Larimar Therapeutics

Mar-04	Larimar Therapeutics to Participate in Upcoming Investor Conferences in March LRMR GlobeNewswire
Feb-25	Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering LRMR -7.23% GlobeNewswire
Feb-25	Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering LRMR +61.25% LRMR -7.23% GlobeNewswire
Feb-24	Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026 LRMR +31.32% GlobeNewswire
Dec-18	Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference LRMR GlobeNewswire
Nov-05	Larimar Therapeutics Reports Third Quarter 2025 Financial Results LRMR -15.26% GlobeNewswire
Sep-29	Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia LRMR -33.66% GlobeNewswire
Sep-28	Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia LRMR GlobeNewswire
Aug-14	Larimar Therapeutics Reports Second Quarter 2025 Financial Results LRMR +14.52% GlobeNewswire
Jul-31	Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares LRMR GlobeNewswire
Jul-29	Larimar Therapeutics Announces Pricing of Underwritten Public Offering LRMR GlobeNewswire
Jul-29	Larimar Therapeutics Announces Proposed Underwritten Public Offering LRMR GlobeNewswire
Jul-08	Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia LRMR GlobeNewswire
Jun-23	Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program LRMR -6.56% GlobeNewswire
Jun-20	Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia LRMR -5.47% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)